F8IL10
Phase 1Small molecule
F8IL10 is one of 9 small molecule programs targeting Rheumatoid Arthritis (RA). It is currently in Phase 1.
1
Indications
4
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Rheumatoid Arthritis (RA)
#DrugCompanyPhaseTrials
1TLL-018
HHangzhou Highlightll Pharmaceutical Co., Ltd
Phase 2
Trexall
Jazz PharmaceuticalsPreclinical
Anti-CD19 CAR-T Cells
TThe Children's Hospital of Zhejiang University School of Medicine
Phase 1
JAB-8263
JJacobio Pharmaceuticals Co., Ltd.
Phase 2
Rapcabtagene Autoleucel
NovartisPreclinical
Allogeneic NK Cells
AArtiva Biotherapeutics, Inc.
Phase 2
Lmy-922
LLuminary Therapeutics
Phase 1
F8IL10
PPhilogen S.p.A.
Phase 1
Conventional Synthetic DMARD
SSecondWave Systems Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Phase II Clinical Trial1 trial
Rheumatoid Arthritis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F8IL10. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- PPhilogen S.p.A.